Amblyopia or Lazy Eye

Amblyopia or lazy eye, is a condition in which the vision in one eye is reduced. It’s normally caused by a misalignment in the eyes or a difference in the images between the 2 eyes.  When the brain receives a clear image and a blurred one,or sees double,  it chooses to “shut off” the blurred eye.

When one eye needs a stronger prescription then the other and is uncorrected, the brain receives a clear image and a blurred image . This causes suppression of the blurred one and over time the vision in that eye deteriorates. It can become impossible to correct if not treated in a young child.

When an eye is turned the brain receives images that are not on top of each other, which causes double vision. To keep from seeing double, one eye is suppressed and over time the vision in that eye deteriorates.

Amblyopia is treated by the use of surgery ( in the case of an eye turn), glasses, and vision therapy which usually involves patching the better eye. It’s easiest treated when done as early as possible and is difficult to treat after about age 10.

It is important to examine young children’s eyes to be certain that they’re seeing equally out of each eye and that both eyes are working together.

Vision News

  • Alcon Launches AcrySof(R) IQ ReSTOR(R) Toric Intraocular Lens Outside The United States
  • Starting The School Year Right
  • Drug Discovery Tools To Fight Cancer, Blindness To Be Discussed At UB Symposium
  • 'Back-To-School' How To Prevent Sports Related Eye Injuries
  • Carl Zeiss Meditec Is Shaping The Future Of Ophthalmology: Creating What's To Come
  • OptiMedica's Laser Cataract Surgery System To Be Featured In Three Clinical Presentations At ESCRS 2010
  • Dr. Tom Tooma Purchases Interest In All 12 Southern California TLC Laser Eye Centers, Changing Name To NVISION Laser Eye Centers
  • Bausch + Lomb Releases Single-Use Vitreoretinal Asymmetric Peeling Forceps
  • New Data Will Help Predict Vision Loss In Glaucoma
  • Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results
  • ReVision's Fenretinide (RT-101) Reduced Incidence Of Choroidal Neovascularization By More Than 50 Percent In Patients With Geographic Atrophy
  • Microplasmin Meets Primary Endpoint In Second Phase III Trial In VMA, Confirms Positive Findings Of First Trial
  • pSivida Announces Iluvien(R) Receives FDA Priority Review For Treatment Of Diabetic Macular Edema
  • Allergan Receives FDA Approval For LUMIGAN(R) 0.01% As First-Line Therapy Indicated For The Reduction Of Elevated Intraocular Pressure In Glaucoma
  • Improving Ocular Disease Screening By LED Illumination Of The Eye
  • Eyegenix™ Artificial Cornea Achieves Major Advancement Towards Curing Corneal Blindness
  • Diabetic Macular Edema Drug Iluvien Gets FDA Priority Review
  • Optometrists Encourage Eye Test For Children, Ireland
  • 'Toolbox Of MiniPromoters' For Gene Research And Therapy Unvelied By UBC Researchers
  • Revolutionary Way To Treat Eye Cancer May Prevent Blindness
  • More...